Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Wilson Therapeutics in connection with its IPO
Mandate

Vinge advised Wilson Therapeutics in connection with its IPO

May 13, 2016

Vinge has advised Wilson Therapeutics AB (publ) in connection with its IPO on Nasdaq Stockholm. The price in the offering was set at SEK 49 per share, corresponding to a
market capitalization of approximately SEK 1,305 million for the total number of outstanding shares in the company (provided that the over-allotment option is utilized).

Vinge’s team primarily consisted of Jesper Ottergren, Erik Sjöman, Christian Lindhé, Ludvig Frithiof, Kristoffer Franzkeit and Astrid Karlsson.

Related

Vinge advises Smart Eye Aktiebolag (publ) on its first SEK 300 million bond issue

 Vinge has advised Smart Eye Aktiebolag (publ) (“Smart Eye”) on the company’s first issue of senior unsecured bonds in an aggregate principal amount of SEK 300 million, under a framework of up to SEK 600 million. Skandinaviska Enskilda Banken AB (publ) acted as sole bookrunner in connection with the bond issue.
December 12, 2025

Vinge advises Nordstjernan in connection with the investment in Circura Group

Vinge has advised Nordstjernan in connection with its investment in newly established Circura Group.
December 12, 2025

Vinge has advised Axcel VI and Currentum in connection with the acquisition of Klarins Rör

 Vinge has advised Axcel VI and the Currentum Group in connection with the acquisition of Klarins Rör i Göteborg AB (“Klarins Rör”).
December 09, 2025